You said, "Not really. The P2s were pretty much done, S had already ACED them, by curing every patient. I think more interesting may be that there never really was a P3, as such."
While the first part of your statement is true, the last part isn't. You probably got the last part about Sovaldi never really having a Phase 3 from Holdencf. A few months back he wrote,
"(GILD) Pharmasset still collecting data in its P3 trial. They received marketing labeling approval after P2. For an unmet medical need with a statistically robust P2 data set don't need P3. ARWR currently enrolling and treating or have treated 350 patients. That number will increase as P2 progresses and is more than enough to secure an FDA labeling approval. Can start marketing with stated commitment to conduct post-marketing P3 as the drug rolls out...."
But the fact is GILD's Sovaldi was only approved after four (4) Phase 3 trials. Holden often shoots from the hip. He is prone to making grand claims that are factually wrong.